Doc, you are always my favorite poster. Mhra is probably doing a high quality job, i dont dispute that but it should not take forever. Six weeks into processing, they can leave a note in their website about nwbo processing for the public to understand . If they asked for additional documentation about a particular thing, it can be documented for the public to see. Nobody will sue their ass. Patients and families can get an idea. Or, LP should cut this silence nonsense and say something in straight words to investors about the delay. My problem is both mhra and nwbo can do better in explaining the unusual delay and they are not. If the science is valid, bring it to the market as quickly as possible, period. Otherwise, tell the world, its not so effective like the company claims. End of story. Imagine a gbm diagnosis in 2021, physicians may tell the patient, help is on the way and imagine that patient ending up dead in feb 2026 waiting for the miracle drug. Iam not writing a movie scenario, i read oncological imaging studies for a living. I know which of the studies may not comeback for follow up scans. I truly feel sad as a cohuman when i see end of the road, kind of disease presentation in somebody. If somebody gets a covid , he or she may not die, unless the immunity is whacked. But for gbm and some other solid malignancies, death will be right, left and center in the conversation. Our drug has the ability to beat these death sentence malignancies and its still not available on shelves. Its a shame on regulatory agencies for slow walking on this. Apologies for the ignorant rant
Bullish
Market Data 
Markets 
